Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloromethane SCHEMBL29246404 | 0.98 | MAPT (0.60) | MAPTAURKAJAK2ABL1NTRK1 | |
| Pyridine SCHEMBL28787917 | 0.90 | MAPT (0.57) | MAPTAURKAJAK2ABL1NTRK1 | |
| Glycine SCHEMBL27658025 | 0.89 | MAPT (0.56) | MAPTAURKAJAK2ABL1NTRK1 | |
| SCHEMBL1765847 | 0.84 | AURKA (0.63) | MAPTAURKAJAK2ABL1NTRK1 | |
| SCHEMBL250171 | 0.84 | CCND3 (0.70) | MAPTAURKAJAK2ABL1NTRK1 | |
| SCHEMBL4696625 | 0.84 | KDM4E (0.57) | MAPTAURKAJAK2ABL1NTRK1 | |
| SCHEMBL5358948 | 0.82 | AURKA (0.61) | MAPTAURKAJAK2ABL1NTRK1 | |
| Hydrochloric Acid SCHEMBL7000982 | 0.82 | CCND3 (0.68) | MAPTAURKAJAK2ABL1NTRK1 | |
| SCHEMBL160155 | 0.82 | AURKA (0.61) | MAPTAURKAJAK2ABL1NTRK1 | |
| SCHEMBL29414293 | 0.82 | AURKA (0.61) | MAPTAURKAJAK2ABL1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | claimed |
| CN-115466275-B | Latent fingerprint fluorescent visual identification probe and method on substrate | 复旦大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119823114-A | Synthesis process of thiabendazole | 江苏诺恩作物科学股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119775125-A | Method, device and application for hydroxylation of benzoic acid or benzoic acid derivative | 上海盛剑微电子有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119735589-A | Improved thiazide preparation method of junling | 江苏诺恩作物科学股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | claimed |
| CN-118406047-A | Synthesis process of thiabendazole | 江苏诺恩作物科学股份有限公司 | 2024-07-30 | — | — | CN | claimed |
| US-20240238274-A1 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASE AND DISORDERS | NORTHWESTERN UNIVERSITY | 2024-07-18 | — | — | US | claimed |
| CN-118307479-A | Method for preparing 2-acetyl benzimidazole by catalysis | 韩素敏 | 2024-07-09 | — | — | CN | claimed |
| CN-118307478-A | Method for preparing thiabendazole intermediate 2-acetyl benzimidazole methyl halide | 韩素敏 | 2024-07-09 | — | — | CN | claimed |
| CN-117683240-A | Method for preparing iron-based MOFs by electron beam irradiation, iron-based MOFs and application | 上海大学 | 2024-03-12 | — | — | CN | claimed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | claimed |
| EP-4326327-A1 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS | Northwestern University (US) | 2024-02-28 | — | — | EP | claimed |
| CN-115466275-A | Fluorescent visual identification probe and method for latent fingerprints on substrate | 复旦大学 | 2022-12-13 | — | — | CN | claimed |
| WO-2022226402-A1 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2022-10-27 | — | — | WO | claimed |
| CN-114989522-A | Deodorant rain shoes | 界首市玉丰塑业有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-114316478-A | Graphene semiconductive shielding material for cable and preparation method thereof | 段恩成 | 2022-04-12 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-12637472-B2 | Benzimidazole heteroatom-containing spiro compound and medicinal use thereof | CHANGZHI UNIVERSITY (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| CN-119823114-B | Synthesis process of thiabendazole | 江苏诺恩作物科学股份有限公司 | 2025-08-29 | — | — | CN | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| CN-119735589-B | Improved thiazide preparation method of junling | 江苏诺恩作物科学股份有限公司 | 2025-08-26 | — | — | CN | disclosed |
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | disclosed |
| US-20250215000-A1 | BENZIMIDAZOLE HETEROATOM-CONTAINING SPIRO COMPOUND AND MEDICINAL USE THEREOF | CHANGZHI UNIVERSITY (CN) | 2025-07-03 | — | — | US | disclosed |
| CN-115466275-B | Latent fingerprint fluorescent visual identification probe and method on substrate | 复旦大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-119823114-A | Synthesis process of thiabendazole | 江苏诺恩作物科学股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119823114-A | Synthesis process of thiabendazole | 江苏诺恩作物科学股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119775125-A | Method, device and application for hydroxylation of benzoic acid or benzoic acid derivative | 上海盛剑微电子有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119735589-A | Improved thiazide preparation method of junling | 江苏诺恩作物科学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119735589-A | Improved thiazide preparation method of junling | 江苏诺恩作物科学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | disclosed |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-11-12 | — | — | US | disclosed |
| CN-110612119-B | Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-10-29 | — | — | CN | disclosed |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-08-13 | — | — | US | disclosed |
| CN-118406047-A | Synthesis process of thiabendazole | 江苏诺恩作物科学股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118406047-A | Synthesis process of thiabendazole | 江苏诺恩作物科学股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240238274-A1 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASE AND DISORDERS | NORTHWESTERN UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118307479-A | Method for preparing 2-acetyl benzimidazole by catalysis | 韩素敏 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307478-A | Method for preparing thiabendazole intermediate 2-acetyl benzimidazole methyl halide | 韩素敏 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307478-A | Method for preparing thiabendazole intermediate 2-acetyl benzimidazole methyl halide | 韩素敏 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307478-A | Method for preparing thiabendazole intermediate 2-acetyl benzimidazole methyl halide | 韩素敏 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307479-A | Method for preparing 2-acetyl benzimidazole by catalysis | 韩素敏 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307479-A | Method for preparing 2-acetyl benzimidazole by catalysis | 韩素敏 | 2024-07-09 | — | — | CN | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| US-20240140945-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-05-02 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117820324-A | Benzimidazole spiro hybrid and medical application thereof | 长治学院 | 2024-04-05 | — | — | CN | disclosed |
| CN-117683240-A | Method for preparing iron-based MOFs by electron beam irradiation, iron-based MOFs and application | 上海大学 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | disclosed |
| EP-4326327-A1 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS | Northwestern University (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4326719-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-02-28 | — | — | EP | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| CN-117177973-A | Pyrido [3,2-D ] pyrimidine compounds and their use for the treatment of proliferative disorders | 蒙特利尔大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116410208-A | Preparation and application of quinoline-pyridyl copper complex | 河南城建学院 | 2023-07-11 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| CN-113336778-B | Fluorescent visual identification probe and method for latent fingerprints on substrate | 复旦大学 | 2022-12-20 | — | — | CN | disclosed |
| CN-115466275-A | Fluorescent visual identification probe and method for latent fingerprints on substrate | 复旦大学 | 2022-12-13 | — | — | CN | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2022221939-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022226402-A1 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-110835333-B | Benzimidazole substituted azole compound and application thereof | 中国药科大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-114989522-A | Deodorant rain shoes | 界首市玉丰塑业有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022174035-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-114316478-A | Graphene semiconductive shielding material for cable and preparation method thereof | 段恩成 | 2022-04-12 | — | — | CN | disclosed |
| CN-107922316-B | FTO inhibitors | 北京生命科学研究所 | 2022-04-08 | — | — | CN | disclosed |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| CN-112062723-B | Preparation method of thiabendazole intermediate | 帕潘纳(北京)科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3894416-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | Global Blood Therapeutics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210317407-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2021-10-14 | — | — | US | disclosed |
| EP-3885337-A1 | FTO INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20210238127-A1 | FTO Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-05 | — | — | US | disclosed |
| WO-2021151265-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10988440-B2 | FTO inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-04-27 | — | — | US | disclosed |
| CN-110615766-B | Disubstituted alpha, beta unsaturated ketone, preparation method and application thereof | 长治学院 | 2021-04-20 | — | — | CN | disclosed |
| CN-112062723-A | Preparation method of thiabendazole intermediate | 帕潘纳(北京)科技有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2020-08-27 | — | — | US | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200148628-A1 | FTO Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-05-14 | — | — | US | disclosed |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2020-03-19 | — | — | US | disclosed |
| CN-110839636-A | Application of benzimidazole derivative in prevention and treatment of agricultural plant diseases | 兰州大学 | 2020-02-28 | — | — | CN | disclosed |
| CN-110835333-A | Benzimidazole substituted azole compound and application thereof | 中国药科大学 | 2020-02-25 | — | — | CN | disclosed |
| CN-110615766-A | Disubstituted alpha, beta unsaturated ketone, preparation method and application thereof | 长治学院 | 2019-12-27 | — | — | CN | disclosed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | disclosed |
| CN-104870630-B | Have the bioreactor of immobilised enzymes, the active improvement method of immobilised enzymes and biological fuel cell | 丰田自动车株式会社 | 2019-11-19 | — | — | CN | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180118665-A1 | FTO Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-03 | — | — | US | disclosed |
| US-9912000-B2 | Fuel cell, manufacturing method thereof, electronic apparatus, enzyme-immobilized electrode, manufacturing method thereof, water-repellent agent, and enzyme immobilizing material | SONY CORPORATION (JP) | 2018-03-06 | — | — | US | disclosed |
| US-9793587-B2 | Electrode material, electrode, and battery | SONY CORPORATION (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9742020-B2 | Fuel cell | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20170237135-A1 | ELECTRODE MATERIAL, ELECTRODE, AND BATTERY | MURATA MANUFACTURING CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9647305-B2 | Electrode material, electrode, and battery | SONY CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9620804-B2 | Fuel cell and method for manufacturing the same, electronic apparatus, enzyme-immobilized electrode and method for manufacturing the same, water-repellent agent, and enzyme-immobilizing material | SONY CORPORATION (JP) | 2017-04-11 | — | — | US | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| CN-104140415-B | Alpha, beta unsaturated ketone compounds containing benzo five-membered unsaturated heterocycle structures as well as preparation method and application of compounds | 中国医学科学院医药生物技术研究所 | 2017-02-15 | — | — | CN | disclosed |
| CN-106349235-A | Novel process for producing thiabendazole | 孟宪锋 | 2017-01-25 | — | — | CN | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| WO-2016073847-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20150357668-A1 | FUEL CELL | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2015-12-10 | — | — | US | disclosed |
| US-20150315549-A1 | BIOREACTOR COMPRISING IMMOBILIZED ENZYME, METHOD FOR IMPROVING ACTIVITY OF IMMOBILIZED ENZYME, AND BIOFUEL CELL | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-1603957-B1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | INEOS SALES UK LTD (GB) | 2015-10-28 | — | — | EP | disclosed |
| EP-1603957-B1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | INEOS SALES UK LTD (GB) | 2015-10-28 | — | — | EP | disclosed |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150280266-A1 | BIOFUEL CELL, METHOD FOR PRODUCTION OF BIOFUEL CELL, ELECTRONIC DEVICE, ENZYME IMMOBILIZATION ELECTRODE, METHOD FOR PRODUCTION OF ENZYME IMMOBILIZATION ELECTRODE, ELECTRODE FOR PRODUCTION OF ENZYME IMMOBILIZATION ELECTRODE, METHOD FOR 5 PRODUCTION OF ELECTRODE FOR PRODUCTION OF ENZYME IMMOBILIZATION ELECTRODE AND ENZYME REACTION USING DEVICE | TOHOKU MURATA MANUFACTURING CO., LTD. (JP) | 2015-10-01 | — | — | US | disclosed |
| CN-104854748-A | Fuel cell | TOYOTA MOTOR CORP | 2015-08-19 | — | — | CN | disclosed |
| US-20150093657-A1 | DIRECT ALUMINUM FUEL CELL AND ELECTRONIC DEVICE | SONY CORPORATION (JP) | 2015-04-02 | — | — | US | disclosed |
| US-8956772-B2 | Fuel cell, and power supply device and electronic apparatus using the same | SONY CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | ANORMED, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | ANORMED, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-8911908-B2 | Fuel cell and enzyme electrode | SONY CORPORATION (JP) | 2014-12-16 | — | — | US | disclosed |
| US-20140287328-A1 | METHOD FOR PRODUCING FUEL BATTERY, AND FUEL BATTERY AND ELECTRONIC DEVICE | SONY CORPORATION (JP) | 2014-09-25 | — | — | US | disclosed |
| US-20140272608-A1 | MULTICOPPER OXIDASE MUTANT, A GENE CODING THEREOF, AND A BIOFUEL-CELL USING THE SAME | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2014-09-18 | — | — | US | disclosed |
| US-20140273183-A1 | SUBSTRATE DETECTION DEVICE AND BIOFUEL CELL WITH SUBSTRATE DETECTION FUNCTION | SONY CORPORATION (JP) | 2014-09-18 | — | — | US | disclosed |
| US-8808928-B2 | Fuel cell, method for operating the same, and electronic device | SONY CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2764567-A1 | A MULTICOPPER OXIDASE MUTANT, A GENE CODING THEREOF, AND A BIOFUEL-CELL USING THE SAME | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-20140220459-A1 | ELECTRODE MATERIAL, ELECTRODE, AND BATTERY | SONY CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8778967-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778967-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140065494-A1 | FUEL CELL, METHOD FOR PRODUCING FUEL CELL, ELECTRONIC APPARATUS, NICOTINAMIDE ADENINE DINUCLEOTIDE-IMMOBILIZED ELECTRODE, NICOTINAMIDE ADENINE DINUCLEOTIDE-IMMOBILIZED CARRIER, ENZYME REACTION UTILIZATION DEVICE, PROTEIN-IMMOBILIZED ELECTRODE AND PROTEIN-IMMOBILIZED CARRIER | SONY CORPORATION (JP) | 2014-03-06 | — | — | US | disclosed |
| US-20140024102-A1 | MICROBIAL FUEL CELL, FUEL AND MICROBES FOR SAID FUEL CELL, BIOREACTOR AND BIOSENSOR | SONY CORPORATION | 2014-01-23 | — | — | US | disclosed |
| EP-2672559-A1 | FUEL CELL, METHOD FOR MANUFACTURING FUEL CELL, ELECTRONIC APPARATUS, NICOTINAMIDE ADENINE DINUCLEOTIDE-IMMOBILIZED ELECTRODE, NICOTINAMIDE ADENINE DINUCLEOTIDE-IMMOBILIZED CARRIER, DEVICE USING ENZYME REACTION, PROTEIN-IMMOBILIZED ELECTRODE, AND PROTEIN-IMMOBILIZED CARRIER | Sony Corporation (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| CN-103204849-A | Method for preparing thiabendazole | UNIV HEILONGJIANG | 2013-07-17 | — | — | CN | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8440333-B2 | Fuel cell and electronic apparatus | SONY CORPORATION (JP) | 2013-05-14 | — | — | US | disclosed |
| WO-2013051284-A1 | A MULTICOPPER OXIDASE MUTANT, A GENE CODING THEREOF, AND A BIOFUEL-CELL USING THE SAME | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2013-04-11 | — | — | WO | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130011748-A1 | POWER SUPPLY DEVICE AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
| CN-102867976-A | Power supply device and electronic apparatus | SONY CORP | 2013-01-09 | — | — | CN | disclosed |
| US-8338039-B2 | Fuel cell | SONY CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2012-11-29 | — | — | US | disclosed |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2012-11-29 | — | — | US | disclosed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2442394-A1 | FUEL CELL, PROCESS FOR MANUFACTURE OF FUEL CELL, ELECTRONIC DEVICE, ENZYME-IMMOBILIZED ELECTRODE, BIOSENSOR, ENERGY CONVERSION ELEMENT, CELL, CELL ORGANELLE, AND BACTERIUM | Sony Corporation (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20110287312-A1 | BIOFUEL CELL | SONY CORPORATION (JP) | 2011-11-24 | — | — | US | disclosed |
| CN-102255098-A | Biofule cell | SONY CORPORAITON | 2011-11-23 | — | — | CN | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110250511-A1 | BIOFUEL CELL | SONY CORPORATION (JP) | 2011-10-13 | — | — | US | disclosed |
| CN-102214835-A | Biofuel cell | SONY CORP | 2011-10-12 | — | — | CN | disclosed |
| US-20110236770-A1 | FUEL CELL AND ENZYME ELECTRODE | SONY CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| CN-102171880-A | Fuel cell and enzyme electrode | SONY CORP | 2011-08-31 | — | — | CN | disclosed |
| US-20110200889-A1 | FUEL CELL, ELECTRONIC DEVICE, AND BUFFER SOLUTION FOR FUEL CELL | SONY CORPORATION (JP) | 2011-08-18 | — | — | US | disclosed |
| CN-101712677-B | Probenazole production process | XUZHOU NOON AGRO CHEMICAL CO LTD | 2011-08-17 | — | — | CN | disclosed |
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110171541-A1 | FUEL CELL, METHOD FOR OPERATING THE SAME, AND ELECTRONIC DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| CN-102124598-A | Fuel cell, process for manufacture of fuel cell, electronic device, enzyme-immobilized electrode, biosensor, energy conversion element, cell, cell organelle, and bacterium | SONY CORP | 2011-07-13 | — | — | CN | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2337134-A1 | FUEL CELL, ELECTRONIC DEVICE AND BUFFER SOLUTION FOR FUEL CELL | Sony Corporation (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110143223-A1 | FUEL CELL | SONY CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110143225-A1 | FUEL CELL AND METHOD FOR MANUFACTURING THE SAME, ELECTRONIC APPARATUS, ENZYME-IMMOBILIZED ELECTRODE AND METHOD FOR MANUFACTURING THE SAME, WATER-REPELLENT AGENT, AND ENZYME-IMMOBILIZING MATERIAL | SONY CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
| CN-102097641-A | Fuel cell | SONY CORP | 2011-06-15 | — | — | CN | disclosed |
| US-20110136022-A1 | FUEL CELL, METHOD FOR PRODUCING FUEL CELL, ELECTRONIC APPARATUS, ENZYME-IMMOBILIZED ELECTRODE, BIOSENSOR, ENERGY-CONVERSION ELEMENT, CELLS, ORGANELLES, AND BACTERIA | SONY CORPORATION (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-1937264-B1 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK SHARP & DOHME (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110117453-A1 | FUEL REFORMER AND POWER GENERATION APPARATUS USING THE SAME | SONY CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| CN-102027623-A | Fuel cell, method for production of fuel cell, electronic device, enzyme-immobilized electrode, biosensor, bioreactor, energy conversion element, and enzymatic reaction-utilizing apparatus | SONY CORP | 2011-04-20 | — | — | CN | disclosed |
| US-20110076736-A1 | FUEL CELL, METHOD FOR MANUFACTURING FUEL CELL, ELECTRONIC APPARATUS, ENZYME IMMOBILIZATION ELECTRODE, BIOSENSOR, BIOREACTOR, ENERGY CONVERSION ELEMENT, AND ENZYME REACTION-UTILIZING APPARATUS | SONY CORPORATION (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2302722-A1 | FUEL CELL, METHOD FOR PRODUCTION OF THE FUEL CELL, ELECTRONIC DEVICE, ENZYME-IMMOBILIZED ELECTRODE, METHOD FOR PRODUCTION OF THE ELECTRODE, WATER-REPELLENT AGENT, AND ENZYME-IMMOBILIZED MATERIAL | Sony Corporation (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110059374-A1 | FUEL CELL AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2011-03-10 | — | — | US | disclosed |
| EP-2287956-A1 | FUEL CELL, METHOD FOR PRODUCTION OF FUEL CELL, ELECTRONIC DEVICE, ENZYME-IMMOBILIZED ELECTRODE, BIOSENSOR, BIOREACTOR, ENERGY CONVERSION ELEMENT, AND ENZYMATIC REACTION-UTILIZING APPARATUS | Sony Corporation (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-7893091-B2 | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893091-B2 | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110039165-A1 | FUEL CELL AND METHOD FOR MANUFACTURING THE SAME, ENZYME-IMMOBILIZED ELECTRODE AND METHOD FOR MANUFACTURING THE SAME, AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2275412-A1 | Indole and benzimidazole derivatives | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100310946-A1 | NEW FUEL CELL, AND POWER SUPPLY DEVICE AND ELECTRONIC APPARATUS USING THE SAME | SONY CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2259374-A1 | FUEL CELL AND ELECTRONIC DEVICE | Sony Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| CN-101884131-A | New fuel cell, and power supply device and electronic device using the fuel cell | SONY CORP | 2010-11-10 | — | — | CN | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100248042-A1 | FUEL CELL, MANUFACTURING METHOD THEREOF, ELECTRONIC APPARATUS, ENZYME-IMMOBILIZED ELECTRODE, MANUFACTURING METHOD THEREOF, WATER-REPELLENT AGENT, AND ENZYME IMMOBILIZING MATERIAL | SONY CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100221644-A1 | FUEL CELL AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2216848-A1 | FUEL CELL, METHOD OF MANUFACTURING SAME, ELECTRONIC DEVICE, IMMOBILIZED-ENZYME ELECTRODE, METHOD OF MANUFACTURING SAME, WATER REPELLENT AGENT, AND ENZYME IMMOBILIZATION MATERIAL | Sony Corporation (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-2216847-A1 | NEW FUEL CELL, AND POWER SUPPLY DEVICE AND ELECTRONIC DEVICE USING THE FUEL CELL | Sony Corporation (JP) | 2010-08-11 | — | — | EP | disclosed |
| CN-101712677-A | Probenazole production process | XUZHOU NOON AGRO CHEMICAL CO L | 2010-05-26 | — | — | CN | disclosed |
| EP-2182571-A1 | FUEL CELL, METHOD FOR OPERATING THE SAME, AND ELECTRONIC DEVICE | Sony Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2175830-A2 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | L'Oreal (FR) | 2010-04-21 | — | — | EP | disclosed |
| CN-101682070-A | Fuel cell and electronic equipment | SONY CORP | 2010-03-24 | — | — | CN | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010025295-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025295-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100047670-A1 | ENZYME-IMMOBILIZED ELECTRODE, FUEL CELL, ELECTRONIC DEVICE, APPARTUS UTILIZING ENZYME REACTION, AND ENZYME-IMMOBILIZED SUBSTRATE | SONY CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2157652-A1 | FUEL CELL AND ELECTRONIC EQUIPMENT | Sony Corporation (JP) | 2010-02-24 | — | — | EP | disclosed |
| CN-101641821-A | Enzyme immobilized electrode, fuel cell, electronic equipment, enzyme reaction utilization apparatus, and enzyme immobilized base | SONY CORP | 2010-02-03 | — | — | CN | disclosed |
| EP-2131437-A1 | ENZYME IMMOBILIZED ELECTRODE, FUEL CELL, ELECTRONIC EQUIPMENT, ENZYME REACTION UTILIZATION APPARATUS, AND ENZYME IMMOBILIZED BASE | Sony Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| CN-101494296-A | Biofuel cell, method for producing the same, electronic apparatus, enzyme-immobilized electrode, and method for producing the same | SONY CORP (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-7531538-B2 | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531538-B2 | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| EP-2028712-A2 | Biofuel cell, method for producing the same, electronic apparatus, enzyme-immobilized electrode, and method for producing the same | Sony Corporation (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20090047567-A1 | Biofuel cell, method for producing the same, electronic apparatus, enzyme-immobilized electrode, and method for producing the same | SONY CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090047550-A1 | METHOD FOR MANUFACTURING FUEL CELL, FUEL CELL, AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| WO-2009016061-A2 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | L'OREAL (FR) | 2009-02-05 | — | — | WO | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| US-7468437-B2 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468437-B2 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080280184-A1 | FUEL CELL, METHOD FOR MANUFACTURING FUEL CELL, AND ELECTRONIC APPARATUS | SONY CORPORATION (JP) | 2008-11-13 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| CN-100415722-C | 2-acetyl benzimidazolyl-glycin schiff base preparation method | UNIV NORTHWESTERN (CN) | 2008-09-03 | — | — | CN | disclosed |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2008-07-10 | — | — | US | disclosed |
| EP-1465889-A4 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC (CA) | 2008-05-14 | — | — | EP | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070269603-A1 | Conductive Fine Particle, Method for Producing Conductive Fine Particle and Electroless Silver Plating Liquid | SEKISUI CHEMICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7232817-B2 | α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232817-B2 | α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| CN-1970545-A | 2-acetyl benzimidazolyl-glycin schiff base preparation method | UNIV NORTHWESTERN (CN) | 2007-05-30 | — | — | CN | disclosed |
| EP-1783783-A1 | CONDUCTIVE FINE PARTICLE, METHOD FOR PRODUCING CONDUCTIVE FINE PARTICLE AND ELECTROLESS SILVER PLATING LIQUID | SEKISUI CHEMICAL CO., LTD. (JP) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007044296-A2 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK & CO., INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7202258-B2 | α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202258-B2 | α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| US-20060094588-A1 | Polymerisation and oligomerisation catalysts | BARCLAYS BANK PLC (GB) | 2006-05-04 | — | — | US | disclosed |
| EP-1628533-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-03-01 | — | — | EP | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| EP-1603957-A1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | Innovene Europe Limited (GB) | 2005-12-14 | — | — | EP | disclosed |
| CN-1699374-A | 2-acetyl benzimidazole condensed glycine Schiff base rare earth complex and preparation method thereof | UNIV NORTHWEST (CN) | 2005-11-23 | — | — | CN | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092142-A1 | AN IMPROVED PROCESS FOR MANUFACTURE OF SUBSTITUTED BENZIMIDAZOLES | IPCA LABORATORIES LIMITED (IN) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
| EP-1465889-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | AnorMED Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004083263-A1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | INNOVENE EUROPE LIMITED (GB) | 2004-09-30 | — | — | WO | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| CN-1317965-A | Compounds having IgE affecting properties | AVANIR PHARMACEUTICALS (US) | 2001-10-17 | — | — | CN | disclosed |
| US-3755314-A | NOVEL 2-ACRYLOYL BENZIMIDAZOLES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC APPLICATION | DELALANDE SA | 1973-08-28 | — | — | US | disclosed |
| US-3755314-A | NOVEL 2-ACRYLOYL BENZIMIDAZOLES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC APPLICATION | DELALANDE SA | 1973-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542233-B2 | Compounds, compositions and methods of use | FUS, TFEB, CLN6 | MAPT 64/4885AURKA 2287/4885JAK2 2804/4885 |
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | MAPT 3479/4885AURKA 91/4885JAK2 145/4885 |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | MAPT 2948/4885AURKA 2164/4885JAK2 393/4885 |
| US-12637472-B2 | Benzimidazole heteroatom-containing spiro compound and medicinal use thereof | NUTF2, CASP3, TP53 | MAPT 3989/4885AURKA 428/4885JAK2 564/4885 |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | MAPT 64/4885AURKA 2287/4885JAK2 2804/4885 |
| US-20180118665-A1 | FTO Inhibitors | FTO, ALKBH3, ALKBH1 | MAPT 3510/4885AURKA 4263/4885JAK2 1276/4885 |
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MAPT 1478/4885AURKA 3981/4885JAK2 2969/4885 |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | MAPT 2279/4885AURKA 2789/4885JAK2 3600/4885 |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MAPT 1478/4885AURKA 3981/4885JAK2 2969/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | MAPT 4186/4885AURKA 114/4885JAK2 156/4885 |
| US-20240140945-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | MAPT 2948/4885AURKA 2164/4885JAK2 393/4885 |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | MAPT 3915/4885AURKA 2848/4885JAK2 3360/4885 |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-20210238127-A1 | FTO Inhibitors | FTO, ALKBH3, ALKBH1 | MAPT 3510/4885AURKA 4263/4885JAK2 1276/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-20250215000-A1 | BENZIMIDAZOLE HETEROATOM-CONTAINING SPIRO COMPOUND AND MEDICINAL USE THEREOF | NUTF2, TP53, PGC | MAPT 4353/4885AURKA 306/4885JAK2 2061/4885 |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | MAPT 2948/4885AURKA 2164/4885JAK2 393/4885 |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | MAPT 4849/4885AURKA 4717/4885JAK2 891/4885 |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | PDE10A, PDE1B, PDE9A | MAPT 136/4885AURKA 4422/4885JAK2 495/4885 |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MAPT 1478/4885AURKA 3981/4885JAK2 2969/4885 |
| US-20240238274-A1 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASE AND DISORDERS | USP19, USP24, USP2 | MAPT 3525/4885AURKA 3769/4885JAK2 2200/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | MAPT 2948/4885AURKA 2164/4885JAK2 393/4885 |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | MAPT 417/4885AURKA 990/4885JAK2 865/4885 |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | SLC40A1, HAMP, SFXN1 | MAPT 4429/4885AURKA 4845/4885JAK2 455/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | MAPT 2948/4885AURKA 2164/4885JAK2 393/4885 |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-20200148628-A1 | FTO Inhibitors | FTO, ALKBH3, ALKBH1 | MAPT 3510/4885AURKA 4263/4885JAK2 1276/4885 |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | MAPT 2279/4885AURKA 2789/4885JAK2 3600/4885 |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MME, UTS2R, BPHL | MAPT 2266/4885AURKA 1899/4885JAK2 2111/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | MAPT 3015/4885AURKA 2197/4885JAK2 421/4885 |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | TACR1, NPSR1, TACR2 | MAPT 3243/4885AURKA 1127/4885JAK2 329/4885 |
| US-20060094588-A1 | Polymerisation and oligomerisation catalysts | CCNA1, AP2M1, AP2A1 | MAPT 4597/4885AURKA 1709/4885JAK2 1583/4885 |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | MAPT 3589/4885AURKA 2604/4885JAK2 522/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | MAPT 417/4885AURKA 990/4885JAK2 865/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-10988440-B2 | FTO inhibitors | FTO, ALKBH3, ALKBH1 | MAPT 3510/4885AURKA 4263/4885JAK2 1276/4885 |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | MAPT 4637/4885AURKA 4254/4885JAK2 1498/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | MAPT 3288/4885AURKA 2406/4885JAK2 686/4885 |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | TRPV1, TRPV2, TRPV3 | MAPT 2690/4885AURKA 2712/4885JAK2 402/4885 |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | MAPT 4625/4885AURKA 4523/4885JAK2 669/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | MAPT 4426/4885AURKA 3929/4885JAK2 338/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | MAPT 4456/4885AURKA 3245/4885JAK2 2053/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | MAPT 3015/4885AURKA 2197/4885JAK2 421/4885 |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | SLC40A1, HAMP, TFRC | MAPT 4182/4885AURKA 4822/4885JAK2 1516/4885 |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | MAPT 4637/4885AURKA 4254/4885JAK2 1498/4885 |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | MAPT 417/4885AURKA 990/4885JAK2 865/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | MAPT 4637/4885AURKA 4254/4885JAK2 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.